Thanks for providing everyone reality checks. I k
Post# of 30027
I see a trend right now (based on the many biotechs that I follow) that are plowing resources into fewer pipeline assets that have the most promise. If the market drops further and financing/funding dries up.....and the Elto results came in with poor results (the company will be in big trouble for a multitude of reasons).
ESS will be a winner (so I look at the company's strategy as becoming more de-risked in the S/T). Once funding is secured..the full pipeline will be in play once again). So whatever keeps the stock price moving up.. going forward (I will agree with this new strategy for now).